The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
